AQR Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.48M | Buy |
7,437
+2,279
| +44% | +$451K | ﹤0.01% | 2553 |
|
|
2025
Q4 | $975K | Buy |
5,158
+574
| +13% | +$110K | ﹤0.01% | 2570 |
|
|
2025
Q3 | $812K | Buy |
4,584
+1,226
| +37% | +$182K | ﹤0.01% | 2552 |
|
|
2025
Q2 | $382K | Buy |
3,358
+23
| +0.7% | +$2.46K | ﹤0.01% | 2746 |
|
|
2025
Q1 | $344K | Buy |
+3,335
| New | +$377K | ﹤0.01% | 2627 |
|
|
2024
Q3 | – | Sell |
-4,924
| Closed | -$407K | – | 2830 |
|
|
2024
Q2 | $407K | Sell |
4,924
-17,641
| -78% | -$1.4M | ﹤0.01% | 2149 |
|
|
2024
Q1 | $1.62M | Sell |
22,565
-30,561
| -58% | -$2.25M | ﹤0.01% | 1493 |
|
|
2023
Q4 | $3.79M | Sell |
53,126
-8,061
| -13% | -$476K | 0.01% | 1070 |
|
|
2023
Q3 | $3.67M | Buy |
61,187
+12,918
| +27% | +$850K | 0.01% | 1057 |
|
|
2023
Q2 | $3.48M | Sell |
48,269
-4,255
| -8% | -$319K | 0.01% | 1047 |
|
|
2023
Q1 | $3.8M | Buy |
52,524
+21,416
| +69% | +$1.52M | 0.01% | 1010 |
|
|
2022
Q4 | $2.05M | Sell |
31,108
-14,800
| -32% | -$962K | ﹤0.01% | 1239 |
|
|
2022
Q3 | $2.47M | Buy |
45,908
+17,674
| +63% | +$1.04M | 0.01% | 1115 |
|
|
2022
Q2 | $1.53M | Buy |
28,234
+15,969
| +130% | +$906K | ﹤0.01% | 1236 |
|
|
2022
Q1 | $861K | Buy |
12,265
+8,713
| +245% | +$632K | ﹤0.01% | 1606 |
|
|
2021
Q4 | $342K | Sell |
3,552
-2,107
| -37% | -$195K | ﹤0.01% | 1942 |
|
|
2021
Q3 | $492K | Sell |
5,659
-15,074
| -73% | -$1.17M | ﹤0.01% | 1871 |
|
|
2021
Q2 | $1.7M | Buy |
20,733
+11,961
| +136% | +$995K | ﹤0.01% | 1315 |
|
|
2021
Q1 | $834K | Sell |
8,772
-36,832
| -81% | -$3.48M | ﹤0.01% | 1631 |
|
|
2020
Q4 | $2.83M | Buy |
45,604
+4,356
| +11% | +$248K | 0.01% | 994 |
|
|
2020
Q3 | $2.45M | Sell |
41,248
-28,978
| -41% | -$1.98M | ﹤0.01% | 1017 |
|
|
2020
Q2 | $4.9M | Sell |
70,226
-209,021
| -75% | -$13.3M | 0.01% | 794 |
|
|
2020
Q1 | $12.7M | Sell |
279,247
-52,310
| -16% | -$2.96M | 0.02% | 570 |
|
|
2019
Q4 | $21.6M | Sell |
331,557
-87,390
| -21% | -$5.84M | 0.02% | 572 |
|
|
2019
Q3 | $26M | Buy |
418,947
+216,863
| +107% | +$13.6M | 0.03% | 523 |
|
|
2019
Q2 | $14.4M | Buy |
202,084
+78,813
| +64% | +$5.8M | 0.02% | 672 |
|
|
2019
Q1 | $9.67M | Buy |
123,271
+22,178
| +22% | +$1.68M | 0.01% | 792 |
|
|
2018
Q4 | $8.56M | Buy |
101,093
+59,383
| +142% | +$6.33M | 0.01% | 775 |
|
|
2018
Q3 | $7.14M | Buy |
41,710
+8,844
| +27% | +$1.33M | 0.01% | 885 |
|
|
2018
Q2 | $4.25M | Buy |
32,866
+4,166
| +15% | +$465K | ﹤0.01% | 1099 |
|
|
2018
Q1 | $2.96M | Buy |
28,700
+4,395
| +18% | +$435K | ﹤0.01% | 1196 |
|
|
2017
Q4 | $2.08M | Buy |
24,305
+11,721
| +93% | +$1.02M | ﹤0.01% | 1362 |
|
|
2017
Q3 | $1.07M | Buy |
+12,584
| New | +$996K | ﹤0.01% | 1647 |
|
|
2017
Q1 | – | Sell |
-12,423
| Closed | -$787K | – | 2220 |
|
|
2016
Q4 | $787K | Sell |
12,423
-29,351
| -70% | -$1.85M | ﹤0.01% | 1776 |
|
|
2016
Q3 | $2.66M | Sell |
41,774
-4,734
| -10% | -$348K | ﹤0.01% | 1283 |
|
|
2016
Q2 | $3.46M | Sell |
46,508
-11,206
| -19% | -$832K | 0.01% | 1055 |
|
|
2016
Q1 | $3.86M | Buy |
57,714
+26,289
| +84% | +$1.6M | 0.01% | 970 |
|
|
2015
Q4 | $2.13M | Buy |
31,425
+11,266
| +56% | +$696K | ﹤0.01% | 1208 |
|
|
2015
Q3 | $1.08M | Buy |
20,159
+8,090
| +67% | +$491K | ﹤0.01% | 1388 |
|
|
2015
Q2 | $760K | Buy |
+12,069
| New | +$659K | ﹤0.01% | 1629 |
|
|
2014
Q4 | – | Sell |
-32,985
| Closed | -$967K | – | 2570 |
|
|
2014
Q3 | $967K | Sell |
32,985
-4,328
| -12% | -$144K | ﹤0.01% | 1628 |
|
|
2014
Q2 | $1.45M | Sell |
37,313
-160
| -0.4% | -$6.49K | ﹤0.01% | 1452 |
|
|
2014
Q1 | $1.57M | Buy |
37,473
+4,007
| +12% | +$167K | ﹤0.01% | 1445 |
|
|
2013
Q4 | $1.1M | Buy |
33,466
+12,661
| +61% | +$413K | ﹤0.01% | 1689 |
|
|
2013
Q3 | $562K | Hold |
20,805
| – | – | ﹤0.01% | 1925 |
|
|
2013
Q2 | $486K | Buy |
+20,805
| New | +$374K | ﹤0.01% | 1909 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
AQR Capital Management's LGND Position: Q1 2026 in Review
AQR Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 44% in Q1 2026, buying an estimated $451K and bringing the position to 7,437 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2553.
AQR Capital Management first reported a position in LGND in Q2 2013 and has held it in 46 quarters since. The position peaked at $26M in Q3 2019. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- AQR Capital Management held 7,437 shares of Ligand Pharmaceuticals worth $1.48M as of Q1 2026.
- AQR Capital Management bought 2,279 Ligand Pharmaceuticals shares in Q1 2026, an estimated $451K.
- Ligand Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2553 holding.
- AQR Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
- AQR Capital Management's Ligand Pharmaceuticals position peaked at $26M in Q3 2019.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.